Radiobiological studies of PC-3 and DU-145 human prostate cancer cells: X-ray sensitivity in vitro and hypoxic fractions of xenografted tumors in vivo von Leith, John T., Quaranto, Lynn, Padfield, Giavanna, Michelson, Seth, Hercbergs, Aleck

Volltext

Modification of the volumetric growth responses and steady-state hypoxic fractions of xenografted DLD-2 human colon carcinomas by administration of basic fibroblast growth factor o... von Leith, JT, Papa, G, Quaranto, L, Michelson, S

Volltext

Effect of preirradiation of transplantation site on growth characteristics and hypoxic fractions in human colon tumor xenografts von LEITH, J. T, PADFIELD, G, QUARANTO, L, MICHELSON, S

Volltext

Modification of the volumetric growth responses and steady-state hypoxic fractions of xenografted DL2-2 human colon carcinomas by administration of basic fibroblast growth factor o... von LEITH, J. T, PAPA, G, QUARANTO, L, MICHELSON, S

Volltext

Cognitive Reserve and Symptom Experience in Multiple Sclerosis: A Buffer to Disability Progression Over Time? von Schwartz, Carolyn E., ScD, Quaranto, Brian R., BS, Healy, Brian C., PhD, Benedict, Ralph H., PhD, Vollmer, Timothy L., MD

Volltext

Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I/II Study von Kitko, Carrie L, Arora, Mukta, DeFilipp, Zachariah, Zaid, Mohammad Abu, Di Stasi, Antonio, Radojcic, Vedran, Betts, Courtney B, Coussens, Lisa M, Meyers, Michael L, Qamoos, Hope, Ordentlich, Peter, Kumar, Vinit, Quaranto, Christine, Schmitt, Aaron, Gu, Yu, Blazar, Bruce R, Wang, Trent P, Salhotra, Amandeep, Pusic, Iskra, Jagasia, Madan, Lee, Stephanie J

Volltext

Collegiate purpose orientations and well-being in early and middle adulthood von Hill, Patrick L., Burrow, Anthony L., Brandenberger, Jay W., Lapsley, Daniel K., Quaranto, Jessica Collado

Volltext

Abstract CT242: SNDX-6352-0502: A phase 1, open-label, dose escalation trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamic activity of SNDX-6352 in... von Tolcher, Anthony W., Rasco, Drew, Sharma, Sunil, Taylor, Matthew, Quaranto, Christine, Tamang, David L., Nordness, Robert, Meyers, Michael L., Sankoh, Serap, Ordentlich, Peter, Azad, Nilo

Volltext

Abstract CT149: SNDX-6352-0502 - A phase 1, open-label, dose escalation trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamic activity of SNDX-6352 mo... von Azad, Nilo, Rasco, Drew, Sharma, Sunil, Taylor, Matthew, Quaranto, Christine, Tamang, David L., Nordness, Robert, Meyers, Michael L., Sankoh, Serap, Ordentlich, Peter, Tolcher, Anthony W.

Volltext

Safety, Tolerability, and Efficacy of Axatilimab, a CSF-1R Humanized Antibody, for Chronic Graft-Versus-Host Disease after 2 or More Lines of Systemic Treatment von Lee, Stephanie J., Arora, Mukta, Defilipp, Zachariah, Abu Zaid, Mohammad Issam, Di Stasi, Antonio, Radojcic, Vedran, Meyers, Michael L., Qamoos, Hope, Ordentlich, Peter, Quaranto, Christine, Schmitt, Aaron, Gu, Yu, Salhotra, Amandeep, Pusic, Iskra, Kitko, Carrie Lynn

Volltext

Results of ENCORE 602 (TRIO025), a phase II, randomized, placebo-controlled, double-blinded, multicenter study of atezolizumab with or without entinostat in patients with advanced... von O'Shaughnessy, Joyce, Moroose, Rebecca L., Babu, Sunil, Baramidze, Kakhaber, Chan, David, Leitner, Stuart P., Nemsadze, Gia, Ordentlich, Peter, Quaranto, Christine, Meyers, Michael L., González Graf, Valeria, Smith, Taunya J., Bee-Munteanu, Valerie, Fresco, Rodrigo, Slamon, Dennis J.

Volltext

Phase 1 Study of Axatilimab (SNDX-6352), a CSF-1R Humanized Antibody, for Chronic Graft-Versus-Host Disease after 2 or More Lines of Systemic Treatment von Arora, Mukta, Jagasia, Madan, Di Stasi, Antonio, Meyers, Michael L, Quaranto, Christine, Schmitt, Aaron, Sankoh, Serap, Abu Zaid, Mohammad Issam, Hill, Geoff R, Weisdorf, Daniel J., Blazar, Bruce R., Ordentlich, Peter, Lee, Stephanie J.

Volltext

Abstract CT179: Safety, efficacy, and immune correlates of alternative doses and schedules of entinostat combined with pembrolizumab in patients with advanced solid tumors - result... von Tolcher, Anthony W., Meyers, Michael L., Gabrilovich, Dmitry, Wang, Fang, Trepel, Jane, Lee, Min-Jung, Schmitt, Emmett, Quaranto, Christine, Sankoh, Serap, Tamang, David, Ordentlich, Peter

Volltext

Safety, Tolerability, and Efficacy of Axatilimab, a CSF-1R Humanized Antibody, for Chronic Graft-Versus-Host Disease after 2 or More Lines of Systemic Treatment von Kitko, Carrie L., Arora, Mukta, Lee, Stephanie J, Zaid, Mohammad Abu, Di Stasi, Antonio, Radojcic, Vedran, Qamoos, Hope, Ordentlich, Peter, Quaranto, Christine, Schmitt, Aaron, Salhotra, Amandeep, Pusic, Iskra, DeFilipp, Zachariah

Volltext

35 - Safety, Tolerability, and Efficacy of Axatilimab, a CSF-1R Humanized Antibody, for Chronic Graft-Versus-Host Disease after 2 or More Lines of Systemic Treatment von Kitko, Carrie L., Arora, Mukta, Lee, Stephanie J, Zaid, Mohammad Abu, Di Stasi, Antonio, Radojcic, Vedran, Qamoos, Hope, Ordentlich, Peter, Quaranto, Christine, Schmitt, Aaron, Salhotra, Amandeep, Pusic, Iskra, DeFilipp, Zachariah

Volltext